Novartis AG PE Ratio 2011-2025 | NVS
Current and historical p/e ratio for Novartis AG (NVS) from 2011 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novartis AG PE ratio as of November 14, 2025 is 14.70.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Novartis AG PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-11-14 | 131.26 | 24.77 | |
| 2025-09-30 | 128.24 | $5.30 | 24.20 |
| 2025-06-30 | 121.01 | $6.87 | 17.61 |
| 2025-03-31 | 111.48 | $6.40 | 17.42 |
| 2024-12-31 | 93.93 | $5.88 | 15.97 |
| 2024-09-30 | 111.02 | $8.61 | 12.89 |
| 2024-06-30 | 102.76 | $7.89 | 13.02 |
| 2024-03-31 | 93.37 | $7.41 | 12.60 |
| 2023-12-31 | 93.87 | $7.18 | 13.07 |
| 2023-09-30 | 89.61 | $3.72 | 24.09 |
| 2023-06-30 | 88.78 | $3.59 | 24.73 |
| 2023-03-31 | 80.94 | $3.25 | 24.90 |
| 2022-12-31 | 76.30 | $3.17 | 24.07 |
| 2022-09-30 | 63.93 | $9.73 | 6.57 |
| 2022-06-30 | 71.09 | $10.23 | 6.95 |
| 2022-03-31 | 73.80 | $10.74 | 6.87 |
| 2021-12-31 | 70.44 | $10.65 | 6.61 |
| 2021-09-30 | 65.86 | $4.33 | 15.21 |
| 2021-06-30 | 73.48 | $3.95 | 18.60 |
| 2021-03-31 | 68.84 | $3.48 | 19.78 |
| 2020-12-31 | 72.95 | $3.52 | 20.72 |
| 2020-09-30 | 67.18 | $3.09 | 21.74 |
| 2020-06-30 | 67.47 | $3.14 | 21.49 |
| 2020-03-31 | 63.69 | $5.24 | 12.16 |
| 2019-12-31 | 70.44 | $5.05 | 13.95 |
| 2019-09-30 | 64.65 | $5.07 | 12.75 |
| 2019-06-30 | 67.93 | $4.87 | 13.95 |
| 2019-03-31 | 63.24 | $5.27 | 12.00 |
| 2018-12-31 | 54.55 | $5.37 | 10.16 |
| 2018-09-30 | 54.77 | $5.70 | 9.61 |
| 2018-06-30 | 48.02 | $5.89 | 8.15 |
| 2018-03-31 | 51.39 | $3.41 | 15.07 |
| 2017-12-31 | 51.35 | $3.25 | 15.80 |
| 2017-09-30 | 52.51 | $2.81 | 18.69 |
| 2017-06-30 | 51.05 | $2.74 | 18.63 |
| 2017-03-31 | 45.42 | $2.66 | 17.08 |
| 2016-12-31 | 42.87 | $2.80 | 15.31 |
| 2016-09-30 | 46.48 | $2.84 | 16.36 |
| 2016-06-30 | 48.57 | $2.80 | 17.34 |
| 2016-03-31 | 42.64 | $2.80 | 15.23 |
| 2015-12-31 | 48.61 | $7.28 | 6.68 |
| 2015-09-30 | 51.93 | $7.45 | 6.97 |
| 2015-06-30 | 55.56 | $7.99 | 6.95 |
| 2015-03-31 | 55.71 | $8.27 | 6.74 |
| 2014-12-31 | 50.81 | $4.14 | 12.27 |
| 2014-09-30 | 51.61 | $4.35 | 11.87 |
| 2014-06-30 | 49.64 | $3.94 | 12.60 |
| 2014-03-31 | 46.62 | $3.94 | 11.83 |
| 2013-12-31 | 42.54 | $3.72 | 11.43 |
| 2013-09-30 | 40.59 | $3.73 | 10.88 |
| 2013-06-30 | 37.42 | $3.84 | 9.74 |
| 2013-03-31 | 37.70 | $3.92 | 9.62 |
| 2012-12-31 | 32.18 | $3.90 | 8.25 |
| 2012-09-30 | 31.15 | $3.55 | 8.77 |
| 2012-06-30 | 28.42 | $3.55 | 8.01 |
| 2012-03-31 | 28.17 | $3.55 | 7.94 |
| 2011-12-31 | 27.74 | $3.80 | 7.30 |
| 2011-09-30 | 27.06 | $4.26 | 6.35 |
| 2011-06-30 | 29.65 | $4.24 | 6.99 |
| 2011-03-31 | 26.37 | $4.19 | 6.29 |
| 2010-12-31 | 27.34 | $4.28 | 6.39 |
| 2010-09-30 | 26.75 | $4.35 | 6.15 |
| 2010-06-30 | 22.41 | $4.28 | 5.24 |
| 2010-03-31 | 25.09 | $4.11 | 6.10 |
| 2009-12-31 | 24.28 | $3.69 | 6.58 |
| 2009-09-30 | 22.47 | $3.34 | 6.73 |
| 2009-06-30 | 18.19 | $3.34 | 5.45 |
| 2009-03-31 | 16.87 | $3.44 | 4.90 |
| 2008-12-31 | 21.18 | $3.59 | 5.90 |
| 2008-09-30 | 22.49 | $3.34 | 6.73 |
| 2008-06-30 | 23.43 | $5.39 | 4.35 |
| 2008-03-31 | 21.81 | $5.26 | 4.15 |
| 2007-12-31 | 22.39 | $5.16 | 4.34 |
| 2007-09-30 | 22.66 | $5.45 | 4.16 |
| 2007-06-30 | 23.12 | $3.28 | 7.05 |
| 2007-03-31 | 22.53 | $3.15 | 7.15 |
| 2006-12-31 | 23.18 | $3.06 | 7.58 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $277.277B | $50.317B |
| Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $969.283B | 46.62 |
| Johnson & Johnson (JNJ) | United States | $472.053B | 18.88 |
| AbbVie (ABBV) | United States | $410.670B | 24.59 |
| Roche Holding AG (RHHBY) | Switzerland | $286.026B | 0.00 |
| Merck (MRK) | United States | $230.630B | 10.74 |
| Novo Nordisk (NVO) | Denmark | $215.481B | 12.63 |
| Pfizer (PFE) | United States | $142.484B | 7.83 |
| Sanofi (SNY) | France | $128.030B | 12.30 |
| Bayer (BAYRY) | Germany | $32.184B | 5.65 |
| Innoviva (INVA) | United States | $1.664B | 8.33 |